Conjugate of antibody and tumor suppressor drug of formula M- [LD] n, or a pharmaceutically acceptable salt thereof, wherein M comprises an anti-DLL3 antibody that specifically binds to an epitope in the DSL domain of a DLL3 protein established as SEQ Id NO: 3 or 4; L comprises an ...
We developed DB-1314, the new anti-DLL3 ADC composed of a novel humanized anti-DLL3 monoclonal antibody (DB131401) conjugated with eight molecules of P1021 (topoisomerase I inhibitor), and described its preclinical profiles. Methods The binding epitope for DB131401 and Rovalpituzumab was tested...
We developed DB-1314, the new anti-DLL3 ADC composed of a novel humanized anti-DLL3 monoclonal antibody (DB131401) conjugated with eight molecules of P1021 (topoisomerase I inhibitor), and described its preclinical profiles.The binding epitope for DB131401 and Rovalpituzumab was tested by bio...
To test this hypothesis, we developed a human CD3ε (hCD3ε) immunocompetent mouse model that has the epitope of human CD3ε, as recognized by TriTAC molecules, specifically knocked-in (KI) to the mouse CD3ε gene. hCD3ε KI mice have comparable immune cell repertoire as wild-type mice...